Conventional multi-step chromatography in downstream purification impacts the overall manufacturing costs, process development (PD) timelines, and manufacturability risks for biopharmaceuticals and vaccines more than any other manufacturing step.
Scil Proteins´ affinity chromatography minimizes this risk and yields highly purified protein in a single-step. Affinity chromatography simplifies PD, reduces number of process steps, shortens development timelines and facilitates robust and scalable processes. In late stage and market supply affinity chromatography significantly reduces time and COGS.
Scil Proteins is dedicated to implement affinity chromatography as a platform driven approach for biopharmaceutical products. It is our mission to deliver solutions for all biological product groups including
- Antibodies, Fab fragments, IgG subtypes
- Non-Antibodies (customized affinity ligands): vaccines, fusion proteins, hormones, blood factors, enzymes etc.
Our ligand platform is fully patent protected in antibody and non-antibody affinity chromatography.
The proprietary affinity ligands have excellent features for stability, affinity, expressability and coupling chemistry.
Our partnering strategy offers the discovery and development of ready-to-use affinity chromatography devices for our customers.